Clinical Trials in Chicago

Showing 10961-10980 of 15,574 trials

Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT00963274

This phase I trial studies the side effects and best dose of giving bortezomib and romidepsin together in treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), indolent B-cell lymphoma, peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). Bortezomib and romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

LeukemiaLymphoma

Virginia Commonwealth University18 participantsStarted Apr 2010

Chicago, Illinois, United States • Baltimore, Maryland, United States • Chapel Hill, North Carolina, United States +2 more locations

COMPLETEDPhase 22.2 miles

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

NCT00859937

This phase II trial is studying how well dasatinib works in treating patients with malignant salivary gland tumors that have come back after treatment or have spread to other parts of the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Malignant Salivary Gland NeoplasmRecurrent Salivary Gland CarcinomaSalivary Gland Adenoid Cystic Carcinoma+1 more

National Cancer Institute (NCI)55 participantsStarted Mar 2009

Beverly Hills, California, United States • Duarte, California, United States • Los Angeles, California, United States +31 more locations

Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Find Trials by Condition in Chicago

Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer

A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector

A Study in Participants With Type 2 Diabetes Mellitus

Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

Cryoablation of Small Breast Tumors in Early Stage Breast Cancer

Fosamprenavir Versus Other Protease Inhibitors

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

A Study for Patients With Type 1 Diabetes

Enduring Happiness and Continued Self-Enhancement

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus